CIRT is a major new randomized trial sponsored by the US National Heart Lung and Blood Institute. CIRT will directly test whether a common anti-inflammatory drug used for the treatment of rheumatoid arthritis (low dose methotrexate) can reduce the risk of heart attack, stroke, and cardiovascular death in patients who have suffered a prior heart attack.
=> Why worry about inflammation? Inflammation plays a major role in heart attack and stroke. While inflammation is as important as cholesterol and high blood pressure, no clinical trial has tested whether reducing inflammation can reduce rates of these life-threatening disorders.
=> Who is eligible for CIRT? Men and women who have suffered a prior heart attack and who have either type 2 diabetes or metabolic syndrome, two conditions associated with a pro-inflammatory response, are eligible to be screened for CIRT.
Via Seth Bilazarian, MD